Videos

Social workers and case managers may have access to institutional- or hospital-level grants that can reduce financial toxicity for patients undergoing cancer therapy.

Genetic backgrounds and ancestry may hold clues for better understanding pancreatic cancer, which may subsequently mitigate different disparities.

Factors like genetic mutations and smoking may represent red flags in pancreatic cancer detection, said Jose G. Trevino, II, MD, FACS.

Thomas Hope, MD, believes that an NRC initiative to update infiltration guidelines may organically address concerns that H.R. 2541 outlines.

Insurance and distance to a tertiary cancer center were 2 barriers to receiving high-quality breast cancer care, according to Rachel Greenup, MD, MPH.

Experts debate when to introduce chemotherapy, how to manage its cumulative toxicity, and how to de-escalate maintenance regimens.

The panel explores integrating molecular data to guide therapy selection and optimize sequencing strategies after resistance emerges.

Thomas Hope, MD, had not observed an adverse effect attributable to an infiltration across more than a decade of administering nuclear agents at UCSF.

Numerous clinical trials vindicating the addition of immunotherapy to first-line chemotherapy in SCLC have emerged over the last several years.

The panelists investigate emerging molecular testing technologies, focusing on whole genome sequencing and advanced profiling techniques.

The discussion centers on the Imvigor011 trial, comparing its ctDNA-guided intervention approach to prostate cancer monitoring. Dr. Meeks and Dr. Tan explore how this prospective study could transform adjuvant therapy strategies in muscle-invasive bladder cancer (MIBC).

According to John Henson, MD, “What we need are better treatments to control the [brain] tumor once it’s detected.”

First-degree relatives of patients who passed away from pancreatic cancer should be genetically tested to identify their risk for the disease.

Panelists discuss how evolving MRD-driven and immune-based therapies are shaping a personalized future for NDMM management.

Panelists discuss how infection prevention and selective IVIG use are critical for maintaining safety during NDMM combination therapy.

Surgery and radiation chemotherapy can affect immunotherapy’s ability to target tumor cells in the nervous system, according to John Henson, MD.

Thinking about how to sequence additional agents following targeted therapy may be a key consideration in the future of lung cancer care.

Endobronchial ultrasound, robotic bronchoscopy, or other expensive procedures may exacerbate financial toxicity for patients seeking lung cancer care.

Patients with mediastinal lymph node involved-lung cancer may benefit from chemoimmunotherapy in the neoadjuvant setting.

Details updated molecular analyses showing significantly fewer resistance mutations with combination therapy.

Advancements in antibody drug conjugates, bispecific therapies, and other targeted agents may hold promise in lung cancer management.

A lower percentage of patients who were released within 1 year of incarceration received guideline-concurrent care vs incarcerated patients.

Stressing the importance of prompt AE disclosure before they become severe can ensure that a patient can still undergo resection with curative intent.

Key AEs of NALIRIFOX in NAPOLI 3 were GI- and hematologic-related, with favorable rates of neutropenia and less growth factor use vs nab-paclitaxel/gemcitabine in mPDAC.

A collaboration between the Connecticut Departments of Health and Corrections and the COPPER Center aimed to improve outcomes among incarcerated patients.

Thomas Marron, MD, PhD, presented a session on clinical data that established standards of care for stage II and III lung cancer treatment at CFS 2025.

A second case illustrates clinical decision-making after progression on osimertinib, highlighting diagnostic re-biopsy and ctDNA testing.

Martin F. Dietrich, MD, PhD, explains how NALIRIFOX dosing in the NAPOLI 3 trial resulted in lower rates of grade 3/4 neutropenia vs standard therapy for metastatic PDAC.

The conversation shifts to how dual EGFR-MET inhibition reduces resistance mutations and molecular heterogeneity compared with osimertinib monotherapy.